A5000447730- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- Cancer, Hypoxia, and Metabolism
- Esophageal Cancer Research and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Cancer Mechanisms and Therapy
- Growth Hormone and Insulin-like Growth Factors
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metabolism, Diabetes, and Cancer
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Cancer Research and Treatments
- Sphingolipid Metabolism and Signaling
- Peptidase Inhibition and Analysis
- Colorectal Cancer Surgical Treatments
University of Maryland, Baltimore
2015-2025
U-M Rogel Cancer Center
2020-2025
University of Maryland Medical Center
2019-2025
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2014-2022
The University of Texas Health Science Center at San Antonio
2022
The University of Texas Health Science Center at Houston
2022
Chongqing Jiaotong University
2021
National University of Singapore
2020
Penn State Milton S. Hershey Medical Center
2006-2019
The University of Texas MD Anderson Cancer Center
2005-2014
c-Met, a high-affinity receptor for hepatocyte growth factor (HGF), plays critical role in cancer growth, invasion, and metastasis. Hepatocellular carcinoma (HCC) patients with an active HGF/c-Met signaling pathway have significantly worse prognosis. Although targeting the has been proposed treatment of multiple cancers, effect c-Met inhibition HCC remains unclear. The human cell lines Huh7, Hep3B, MHCC97-L, MHCC97-H were used this study to investigate using small molecule selective tyrosine...
7506 Background: The use of single agent cytotoxic or targeted as maintenance following combination therapyrepresents a useful strategy to improve patient outcomes in advanced stage NSCLC. An earlier study with gemcitabine therapy demonstrated improved time progression (TTP) compared BSC (6.6 mos. vs 5.0 mos., p < 0.001) (Brodowicz et al, Lung Cancer, 2006; 52:155-163). Based on this, we conducted randomized phase III compare G + versus for patients Methods: Patients IIIB (wet)/IV NSCLC were...
NRG/RTOG 0848 was designed to determine whether adjuvant radiation with fluoropyrimidine sensitization improved survival following gemcitabine-based chemotherapy for patients resected pancreatic head adenocarcinoma. In step 1 of this protocol, were randomized gemcitabine versus the combination and erlotinib. This manuscript reports final analysis these data.Eligibility-within 10 weeks curative intent pancreaticoduodenectomy postoperative CA19-9<180. Gemcitabine arm-6 cycles gemcitabine....
<h3>Background and objectives</h3> Hepatocellular carcinoma (HCC) affects an increasing number of people worldwide. The poor survival rate patients with HCC is manifested by aggressive metastatic phenotype, as well a response to common therapeutic strategies. purpose this study was evaluate the efficacy nanoliposomal C6-ceramide antineoplastic agent in vivo model human HCC. <h3>Methods</h3> growth-arresting pro-apoptotic properties were first evaluated vitro SK-HEP-1 cells assessing cellular...
Poor prognosis cancers, such as pancreatic cancer, represent inherent challenges for ceramide-based nanotherapeutics due to metabolic pathways, which neutralize ceramide less toxic or pro-oncogenic metabolites. We have recently developed a novel 80 nanometer diameter liposomal formulation that incorporates 30 molar percent C6-ceramide, bioactive lipid is pro-apoptotic many cancer cells, but not normal cells. In this manuscript, we evaluated the efficacy of combining nanoliposomal C6-ceramide...
The role of signal transducers and activators transcription (STATs) in receptor protein-tyrosine kinase (PTK)-induced cell growth transformation was investigated using an inducible epidermal factor receptor-Ros chimeric called ER2 a constitutively activated insulin-like I NM1, both which are able to induce anchorage-independent NIH 3T3 cells. NM1 PTKs cause Stat3 activation. Co-expressing the dominant negative mutant with or transiently stable transfected cells resulted dramatic inhibition...
Upon T cell activation, IkappaB kinases (IKKs) are transiently recruited to the plasma membrane-associated lipid raft microdomains for activation of NF-kappaB in promoting proliferation. Retroviral Tax proteins from human leukemia virus type 1 and 2 (HTLV-1 -2) capable activating IKK, yet only HTLV-1 infection causes leukemia, which correlates with persistent induced by Tax1. Here, we show that exhibit differential modes IKK activation. The subunits constitutively present rafts activated...
Although numerous genetic mutations and amplifications have been identified in pancreatic cancer, much of the molecular pathogenesis disease remains undefined. While proteomic transcriptomic analyses utilized to probe characterize tumors, lipidomic not applied identify perturbations cancer patient samples. Thus, we a mass spectrometry-based approach, focused towards sphingolipid class lipids, quantify changes human tumor plasma specimens. Subgroup analysis revealed that patients with...
To investigate the potential role of protein kinase C-delta (PKC-delta) in insulin-like growth factor I receptor (IGF-IR)-mediated cell transformation, an oncogenic gag-IGF-IR beta-fusion lacking entire extracellular domain, which was designated NM1, and a full-length IGF-IR were coexpressed with either wild-type PKC-delta (PKC-deltaWT) or ATP-binding mutant (PKC-deltaK376R) NIH 3T3 fibroblasts. While overexpression PKC-deltaWT did not affect NM1- IGF-IR-induced focus colony formation cells,...
744 Background: Advanced pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with limited treatment options. Dysregulated MAPK and PI3K signaling in PDAC activates the eukaryotic translational initiation complex, promoting cell growth, chemoresistance metastatic spread (PMID 25593033). Galeterone, novel steroidal anti-androgen, downregulates critical mediators of this complex including Mnk1/2 phosphorylated eIF4E, thereby blocking epithelial-to-mesenchymal transition NF-kB...
Effective treatment of acute myeloid leukemia (AML) remains an urgent unmet need. Adoptive transfer cytotoxic T cells (CTLs) against leukemia-associated antigen (LAA) has strong potential to improve AML treatment. However, the clinical translation this therapeutic modality is hindered by difficulty obtaining large quantities LAA-specific CTLs. Stimulating naïve using monocyte-derived dendritic (MoDCs) loaded with LAA commonly used for generation This approach drawbacks as MoDCs desired need...
Hepatocellular cancer (HCC), one of the world's most deadly tumors, and its incidence in US continues to rise. Surgical resection/transplantation offers only hope for cure; however, many patients are not candidates have limited therapeutic options. Opioid growth factor (OGF) is a naturally occurring bioactive endogenous pentapeptide that inhibits human HCC cell lines vitro by receptor-mediated mechanism progression tumors nude mice. Based on these preclinical studies, we conducted phase I...